{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:47:44Z","timestamp":1793760464600,"version":"4.6.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020913","name":"Service de Sant\u00e9 des Arm\u00e9es","doi-asserted-by":"publisher","award":["NBC-5-C-2316"],"award-info":[{"award-number":["NBC-5-C-2316"]}],"id":[{"id":"10.13039\/100020913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001671","name":"European Synchrotron Radiation Facility","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0208"],"award-info":[{"award-number":["P1-0208"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["BI-FR\/23-24-PROTEUS-002"],"award-info":[{"award-number":["BI-FR\/23-24-PROTEUS-002"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P4-0127"],"award-info":[{"award-number":["P4-0127"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["N1-0277"],"award-info":[{"award-number":["N1-0277"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["SN-ZRD\/22\\u201327\/0510"],"award-info":[{"award-number":["SN-ZRD\/22\\u201327\/0510"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006021","name":"Direction G\u00e9n\u00e9rale de l\u2019Armement","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007657","name":"Univerza v Ljubljani","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007657","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016398","name":"Minist\u00e8re des Arm\u00e9es","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016398","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.cbi.2025.111681","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:08:00Z","timestamp":1753888080000},"page":"111681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["N-Propargylpyrrolidine-based butyrylcholinesterase and monoamine oxidase inhibitors"],"prefix":"10.1016","volume":"420","author":[{"given":"Urban","family":"Ko\u0161ak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damijan","family":"Knez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Pi\u0161lar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selena","family":"Horvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"\u017dakelj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Igert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Nachon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Brazzolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9678-3083","authenticated-orcid":false,"given":"Stanislav","family":"Gobec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2025.111681_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116569","article-title":"New insights into butyrylcholinesterase: pharmaceutical applications, selective inhibitors and multitarget-directed ligands","volume":"275","author":"Sun","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrn1035","article-title":"Neurobiology of butyrylcholinesterase","volume":"4","author":"Darvesh","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.cbi.2025.111681_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11062-020-09864-3","article-title":"Butyrylcholinesterase in substance abuse: an overview","volume":"52","author":"Nurulain","year":"2020","journal-title":"Neurophysiology"},{"key":"10.1016\/j.cbi.2025.111681_bib4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0301-0082(99)00047-7","article-title":"The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5'butyrylcholinesterase-DNA study","volume":"60","author":"Mack","year":"2000","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.cbi.2025.111681_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/toxics6030052","article-title":"Knockdown of butyrylcholinesterase but not inhibition by chlorpyrifos alters early differentiation mechanisms in human neural stem cells","volume":"6","author":"Tiethof","year":"2018","journal-title":"Toxics"},{"key":"10.1016\/j.cbi.2025.111681_bib6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cbi.2010.01.037","article-title":"Butyrylcholinesterase activity in multiple sclerosis neuropathology","volume":"187","author":"Darvesh","year":"2010","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2025.111681_bib7","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1021\/bi020016x","article-title":"Kinetic and structural studies on the interaction of cholinesterases with the anti-alzheimer drug rivastigmine","volume":"41","author":"Bar-On","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2025.111681_bib8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4155\/fmc-2017-0036","article-title":"Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease","volume":"9","author":"Knez","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejmech.2017.03.062","article-title":"Recent progress in the identification of selective butyrylcholinesterase inhibitors for alzheimer's disease","volume":"132","author":"Li","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.drudis.2018.11.012","article-title":"Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors","volume":"24","author":"Jing","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cbi.2025.111681_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97404-2","article-title":"Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor","volume":"11","author":"Zako\u0161ek Pipan","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cbi.2025.111681_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118093","article-title":"A novel butyrylcholinesterase inhibitor induces antidepressant, pro-cognitive, and anti-anhedonic effects in flinders sensitive line rats: the role of the ghrelin-dopamine Cascade","volume":"187","author":"Olivier","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cbi.2025.111681_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1021\/cn100090g","article-title":"Cysteine thioesters as myelin proteolipid protein analogues to examine the role of butyrylcholinesterase in myelin decompaction","volume":"2","author":"Pottie","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.cbi.2025.111681_bib14","article-title":"Blocking drug activation as a therapeutic strategy to attenuate acute toxicity and physiological effects of heroin","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cbi.2025.111681_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.cbi.2025.111681_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112787","article-title":"A comprehensive review of monoamine oxidase inhibitors as anti-alzheimer\u2019s disease agents: a review","volume":"206","author":"Manzoor","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114655","article-title":"Monoamine oxidase inhibitors: a concise review with special emphasis on structure activity relationship studies","volume":"242","author":"Bhawna","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib18","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3389\/fphar.2016.00340","article-title":"Inhibitors of MAO-A and MAO-B in psychiatry and neurology","volume":"7","author":"Finberg","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111681_bib19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.molmed.2024.09.010","article-title":"Targeting monoamine oxidases in cancer: advances and opportunities","volume":"31","author":"Wei","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.cbi.2025.111681_bib20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coph.2017.04.003","article-title":"Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease","volume":"33","author":"Deshwal","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111681_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103393","article-title":"Monoamine oxidases: a missing link between mitochondria and inflammation in chronic diseases?","volume":"77","author":"Beucher","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.cbi.2025.111681_bib22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bmc.2016.11.032","article-title":"N-propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: potential multifunctional anti-alzheimer\u2019s agents","volume":"25","author":"Ko\u0161ak","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112282","article-title":"N-alkylpiperidine carbamates as potential anti-alzheimer\u2019s agents","volume":"197","author":"Ko\u0161ak","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib24","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1021\/jm501535r","article-title":"CNS drug design: balancing physicochemical properties for optimal brain exposure","volume":"58","author":"Rankovic Z","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib25","doi-asserted-by":"crossref","first-page":"13483","DOI":"10.1021\/acs.jmedchem.2c00969","article-title":"Recent scaffold hopping applications in central nervous system drug discovery","volume":"65","author":"Callis","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib26","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.tetlet.2014.02.034","article-title":"Straightforward synthesis of orthogonally protected piperidin-3-ylmethanamine and piperidin-4-ylmethanamine derivatives","volume":"55","author":"Ko\u0161ak","year":"2014","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.cbi.2025.111681_bib27","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1021\/acs.jmedchem.5c00577","article-title":"Lead optimization of a butyrylcholinesterase inhibitor for the treatment of Alzheimer's disease","volume":"68","author":"Ko\u0161ak","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib28","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.1021\/jm501195e","article-title":"Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor","volume":"57","author":"Brus","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/acs.jmedchem.7b01086","article-title":"The magic of crystal structure-based inhibitor optimization: development of a butyrylcholinesterase inhibitor with picomolar affinity and in vivo activity","volume":"61","author":"Ko\u0161ak","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/srep39495","article-title":"Development of an in-vivo active reversible butyrylcholinesterase inhibitor","volume":"6","author":"Ko\u0161ak","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cbi.2025.111681_bib31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111681_bib32","doi-asserted-by":"crossref","first-page":"10455","DOI":"10.1021\/jm501501a","article-title":"N-methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor","volume":"24","author":"Bautista-Aguilera","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.phrs.2003.11.017","article-title":"Cholinesterase inhibitors: new roles and therapeutic alternatives","volume":"50","author":"Giacobini","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cbi.2025.111681_bib34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1365-2125.1999.00026.x","article-title":"Acetylcholinesterase inhibitors in Alzheimer's disease","volume":"48","author":"McGleenon","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111681_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/acs.jmedchem.7b01086","article-title":"The magic of crystal structure-based inhibitor optimization: development of a butyrylcholinesterase inhibitor with picomolar affinity and in vivo activity","volume":"61","author":"Ko\u0161ak","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib36","doi-asserted-by":"crossref","first-page":"12684","DOI":"10.1073\/pnas.0505975102","article-title":"Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B","volume":"102","author":"De Colibus","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cbi.2025.111681_bib37","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/acs.jmedchem.9b01886","article-title":"Stereoselective activity of 1-propargyl-4-styrylpiperidine-like analogues that can discriminate between monoamine oxidase isoforms A and B","volume":"63","author":"Knez","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111681_bib38","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1021\/acsmedchemlett.4c00054","article-title":"Fitting of kinact and KI values from endpoint pre-incubation IC50 data","volume":"15","author":"Mader","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.cbi.2025.111681_bib39","first-page":"95","article-title":"Donepezil and rivastigmine: pharmacokinetic profile and brain-targeting after intramuscular administration in rats","volume":"19","author":"Karasova","year":"2020","journal-title":"Iran. J. Pharm. Res. (IJPR)"},{"key":"10.1016\/j.cbi.2025.111681_bib40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid \u03b2-based therapy for Alzheimer's disease: challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.cbi.2025.111681_bib41","unstructured":"The Number of Signals in 13C-NMR Spectrum Exceeds the Number of Carbon Atoms, due to Ring Inversion and N-inversion at Room Temperature, Which Leads to Conformational Isomers."},{"key":"10.1016\/j.cbi.2025.111681_bib42","unstructured":"H. von der Eltz, H.J. Guder, K. Muhlegger K, USP Patent No. 4900822, Feb. 13, 1990."},{"key":"10.1016\/j.cbi.2025.111681_bib43","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1046\/j.0014-2956.2001.02692.x","article-title":"Engineering of a monomeric and low-glycosylated form of human butyrylcholinesterase","volume":"269","author":"Nachon","year":"2002","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.cbi.2025.111681_bib44","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1111\/j.1742-4658.2012.08672.x","article-title":"Human butyrylcholinesterase produced in insect cells: huprine-based affinity purification and crystal structure","volume":"279","author":"Brazzolotto","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.cbi.2025.111681_bib45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"Xds","volume":"66","author":"Kabscha","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.cbi.2025.111681_bib46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1107\/S0907444913000061","article-title":"How good are my data and what is the resolution?","volume":"69","author":"Evans","year":"2013","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.cbi.2025.111681_bib47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.cbi.2025.111681_bib48","first-page":"1074","volume":"vol. 65","author":"Moriarty","year":"2009"},{"key":"10.1016\/j.cbi.2025.111681_bib49","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725003114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725003114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:11:47Z","timestamp":1778638307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279725003114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":49,"alternative-id":["S0009279725003114"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111681","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-Propargylpyrrolidine-based butyrylcholinesterase and monoamine oxidase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111681"}}